GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex ...read more